T1~2期人表皮生长因子受体2阳性型及非阳性型浸润性乳腺癌微钙化特点比较  

Comparison of characteristics of microcalcification in patients with T1~2 stage HER2 positive and non-positive invasive breast cancer

作　　者：马强[1] 杨丽[1] 何建信 张春霞[1] 郝金燕 MA Qiang;YANG Li;HE Jianxin(Department of General Surgery,Beijing Shunyi Hospital,Beijing 101300,China)

机构地区：[1]北京市顺义区医院普外二科,101300 [2]北京市顺义区医院病理科,101300 [3]内蒙古通辽市科尔沁左翼中旗人民医院

出　　处：《临床外科杂志》2022年第2期156-159,共4页Journal of Clinical Surgery

摘　　要：目的 分析T1~2期人表皮生长因子受体2(HER2)阳性型及非阳性型浸润性乳腺癌(IBC)病人微钙化(MC)的特点。方法 T1~2期IBC病人254例,采用乳腺X线诊断系统评估MC形态,分析HER2阳性型及非阳性型者MC发生及特点。结果 MC发生率为53.54%(136/254),HER2阳性型MC的发生率高于非阳性型(79.37%vs 45.03%,P<0.05);HER2阳性型MC以沿导管分布的细线分支样多见,非阳性型以簇状分布针尖样多见,两组间的MC形态及分布比较差异有统计学意义(P<0.05);HER2阳性组中,50岁以上病人MC发生率高于50岁及以下者,差异有统计学意义(P<0.05)。结论 HER2阳性型IBC病人MC发生率更高,MC的形态及分布对HER2表达状态预测有一定指导意义。Objective To analyze the characteristics of breast microcalcification(MC) in patients with T1~2 stage human epidermal growth factor receptor 2(HER2) positive and non-positive invasive breast cancer(IBC).Methods Retrospectively analyzed the clinicopathological data of 254 patients with T1~2 stage IBC.To analyze the occurrence and characteristics of MC in HER2 positive and non-positive patients.Results In this study, the incidence of MC was 53.54%(136/254),The incidence of MC in the HER2 positive group was higher than that in the non-positive group(79.37%vs 45.03%,P<0.05).In HER2 positive group, MC was mainly branching samples of thin lines distributed along ducts, while in non-positive group, it was more common to have needle tip like cluster distribution.There were significant differences in MC morphology and distribution between the two groups(P<0.05).In HER2 positive patients, the incidence of MC in patients who was older than 50 years was higher than that in patients who was 50 years and younger(P<0.05).Conclusion The incidence of MC was higher in HER2-positive IBC patients, and the morphology and distribution of MC had certain guiding significance in predicting the expression status of HER2.

关 键 词：浸润性乳腺癌 人表皮生长因子受体2 微钙化 

分 类 号：R737.9[医药卫生—肿瘤]